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ABSTRACT
DNA interstrand crosslinks (ICLs) are among the
most cytotoxic types of DNA damage, thus ICL-
inducing agents such as psoralen, are clinically
useful chemotherapeutics. Psoralen-modified tri-
plex-forming oligonucleotides (TFOs) have been
used to target ICLs to specific genomic sites to
increase the selectivity of these agents. However,
how TFO-directed psoralen ICLs (Tdp-ICLs) are
recognized and processed in human cells is unclear.
Previously, we reported that two essential nucleo-
tide excision repair (NER) protein complexes,
XPA–RPA and XPC–RAD23B, recognized ICLs
in vitro, and that cells deficient in the DNA mismatch
repair (MMR) complex MutSb were sensitive to psor-
alen ICLs. To further investigate the role of MutSb
in ICL repair and the potential interaction between
proteins from the MMR and NER pathways on
these lesions, we performed electrophoretic mobi-
lity-shift assays and chromatin immunoprecipitation
analysis of MutSb and NER proteins with Tdp-ICLs.
We found that MutSb bound to Tdp-ICLs with high
affinity and specificity in vitro and in vivo, and that
MutSb interacted with XPA–RPA or XPC–RAD23B
in recognizing Tdp-ICLs. These data suggest that
proteins from the MMR and NER pathways interact
in the recognition of ICLs, and provide a mechanis-
tic link by which proteins from multiple repair path-
ways contribute to ICL repair.
INTRODUCTION
DNA interstrand crosslinks (ICLs) can cause a block to
DNA metabolic processes, such as replication and tran-
scription, and are highly cytotoxic (1,2). Thus, ICL-form-
ing compounds have been utilized in chemotherapeutic
regimens to promote cancer cell death (3,4). Triplex-
forming oligonucleotides (TFOs) bind to sites in duplex
DNA in a sequence-speciﬁc fashion to form triple-helical
structures, and when conjugated to a DNA damaging
agent, can be used to direct site-speciﬁc DNA damage
(5). By targeting DNA damaging agents to speciﬁc sites,
drug-conjugated TFOs provide a potential mechanism to
increase speciﬁcity for tumor cells and reduce cytotoxicity
to normal cells. For example, Christensen et al. (6) used
c-MYC-speciﬁc psoralen-modiﬁed TFOs to increase the
incorporation of the anticancer nucleoside analogue gem-
citabine into the targeted DNA in human breast cancer
cells, which led to decreased anchorage-independent
growth and increased cytotoxicity. Therefore, the use of
combinations of TFOs with chemotherapeutic crosslinking
agents may oﬀer a new strategy for cancer treatment.
However, the molecular mechanism(s) by which cells pro-
cess TFO-directed psoralen ICLs (Tdp-ICLs) remains
unclear. In addition, the repair of ICLs alone (in the
absence of the triplex structure) in mammalian cells is still
poorly understood.
In Escherichia coli, both the nucleotide excision repair
(NER) pathway and homologous recombination (HR)
pathway are involved in ICL repair (7,8). Escherichia
coli UvrABC proteins, which function in the NER path-
way are involved in resolving the ICLs (9). After recogni-
tion of the ICLs, the endonuclease complex UvrA2B
recognizes and binds to the ICLs, and then UvrC and
UvrB make 50 and 30 incisions ﬂanking the ICLs, to release
one of the DNA strands with the crosslinking agent still
covalently linked to the other strand, a process called
‘unhooking’ (7,10). DNA polymerase IV binds to the
excised ends and synthesizes the gap without the template,
which is considered an error-prone type of repair. Then,
DNA ligase I joins the end of the synthesized fragment
to the excision. Finally, the strand with the unhooked
fragment is excised by UvrABC and replicated using the
repaired strand as a template, with ligase ﬁlling in the
gap (9).
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plex than that in E. coli. Proteins involved in the mamma-
lian NER pathway, such as XPA, RPA, XPC–RAD23B,
ERCC1, XPF and XPG, have all been reported to func-
tion in ICL repair (11). Among these proteins, the XPC–
RAD23B complex is commonly accepted as the DNA
damage recognition factor (12,13). ERCC1–XPF and
XPG are structure-speciﬁc endonucleases that generate
50 and 30 incisions, respectively, ﬂanking bulky DNA
damage, which is similar to the excision pattern of DNA
damage processed by UvrABC in E. coli (14). In addition
to the NER pathway, the mismatch repair (MMR) protein
complex MutSb (MSH2-MSH3 heterodimer) binds DNA
ICLs in puriﬁed systems and in cell lysates (15). Using a
cell-based assay, Zhang et al. (16) showed that ICLs could
be processed by an error-free homology-dependent recom-
bination repair pathway after introducing a DNA double-
strand break in close proximity to the ICL, and that this
repair was dependent on MSH2, ERCC1–XPF, REV3
and Fanconi anemia proteins.
The repair of Tdp-ICLs may be even more complicated
than that of ICLs alone due to the triple-helical structure
at the site of the ICL. Previously, we reported that two
NER protein complexes (XPA–RPA and XPC–RAD23B)
bind to Tdp-ICLs in vitro (17,18), and that the bacterial
UvrABC nuclease can recognize and incise Tdp-ICLs
in vitro (19). Similar to duplex ICLs, more than one
repair pathway may be involved in the recognition and
processing of Tdp-ICLs. We have shown that the repair
eﬃciency of Tdp-ICLs was reduced in MSH2-deﬁcient
human cell-free extracts, suggesting that MSH2 is
involved in their repair (20). In addition, MSH2-deﬁcient
cells were sensitive to psoralen ICLs, yet the ICL-induced
mutagenesis was similar to that in MSH2-proﬁcient cells,
indicating that the MMR protein MSH2 is involved in an
error-free repair of ICLs (20). Thus, proteins from both
the MMR and NER pathways have been implicated in the
recognition and/or processing of psoralen ICLs in mam-
malian cells. However, it is not known how these proteins
interact in the ﬁrst, and rate-limiting step of repair, i.e.
DNA damage recognition.
In the present study, we investigated the recognition of
Tdp-ICLs by the MMR protein complex MutSb and the
NER protein complexes, XPA–RPA and XPC–RAD23B,
and discovered that MutSb interacts with these two com-
plexes on Tdp-ICLs. At low protein concentrations,
MutSb and XPC–RAD23B bound the psoralen ICLs
independently. However, increasing the concentrations
of MutSb and XPC–RAD23B triggered the formation of
a higher-order complex containing the Tdp-ICL bound to
both protein complexes. In contrast, MutSb formed
higher-order complexes with XPA-RPA on psoralen
ICLs even at low protein concentrations. Chromatin
immunoprecipitation (ChIP) analysis revealed that
MutSb bound to Tdp-ICLs in human cells. Our ﬁndings
suggest that proteins from more than one repair pathway
are involved in the recognition of ICLs in vitro and in vivo,
and that these proteins may participate cooperatively
or independently in ICL repair, depending on their local
concentrations. Understanding the mechanism(s) of ICL
repair in mammalian cells is essential for improving the
eﬃcacy of ICL-inducing chemotherapeutic agents and
preventing the resistance of cancer cells to such treatment.
MATERIALS AND METHODS
TFO-directed psoralen ICL (Tdp-ICL) formation
TFOs were synthesized with the 50-psoralen derivative,
HMT, (2-[40(hydroxymethyl)-4,50,8-trimethylpsoralen]-
hexyl-1-O-(2-cyanoethyl)-N,N-diisopropyl)-phosphorami-
dite) by the Midland Certiﬁed Reagent Company, Inc.
(Midland, TX, USA). Synthetic 57-bp oligonucleotides
were annealed to form the target duplex (Figure 1A, com-
plementary oligonucleotides 71+72), then were 50-end-
labeled with [g-
32P]dATP, and gel puriﬁed as described
previously (17,21). The psoralen-modiﬁed TFO (pAG30,
30-mer) was incubated with duplex target substrate in a
triplex binding buﬀer (10mM Tris–HCl, pH 7.6, 10mM
MgCl2, 10% [v/v] glycerol) in the dark at 378C overnight,
and then irradiated with 1.8J/cm
2 ultraviolet A light at
365nm for 20min to induce the formation of TFO-direc-
ted psoralen ICLs (Tdp-ICLs). The eﬃciency of crosslink-
ing of the psoralen to the duplex targets was up to 90%
as determined by native 12% polyacrylamide gel electro-
phoresis (PAGE).
A psoralen-crosslinked duplex DNA substrate (ICL
only, in the absence of the third strand TFO) was prepared
using the same duplex substrate (71+72) and same TFO
but containing a disulﬁde link between the psoralen deriv-
ative and the TFO (p-s-s-AG30, Midland Certiﬁed
Reagent Company). After triplex formation and UVA
irradiation, the Tdp-ICL was treated with 1/10 volume
of 1M dithiothreitol (DTT) at 658C for 3h to release
the TFO from the ICL. The duplex ICL was then puriﬁed
on a 12% denaturing gel, as we have described (19).
Human recombinant proteins
The plasmid expressing subunits MSH2 and MSH3
of MutSb was constructed by ligation of digested frag-
ments from pFastbacDual-MSH2-MSH6 (22) and
pGEM7Zf(+) plasmid harboring a human MSH3
cDNA (23), respectively. The resulting plasmid
pFastbacDual-MSH2-MSH3 was used to prepare baculo-
virus according to the manufacturer’s (Invitrogen,
Carlsbad, CA, USA) protocol. Recombinant virus was
plaque-puriﬁed, and high titer stocks were prepared and
used to infect Sf9 cells for protein expression.
Recombinant MutSb was puriﬁed from cleared lysates
of infected Sf9 cells by a chromatographic procedure iden-
tical to that described previously for the native human
protein (24). XPA–maltose-binding protein fusion protein
was expressed and puriﬁed from E. coli PR745 (25). The
three subunits of RPA (P70, P32 and P14) were expressed
by co-infection of Sf9 insect cells and puriﬁed by Ni
2+-
chelate column chromatography, as previously described
(26). The XPC–RAD23B–maltose-binding protein fusion
complex was expressed and puriﬁed in Sf9 or Hi-5 insect
cells, as previously described (27).
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DNA–protein complexes were investigated by EMSAs.
The human recombinant puriﬁed protein complexes
MutSb (100ng, 43nM), XPC–RAD23B (10ng, 6.5nM),
and XPA (50ng, 60nM), and RPA (5ng, 5nM) were pre-
incubated in binding buﬀer (37.5mM Tris–HCl, pH 7.6,
150mM NaCl, 1.5mM DTT, 1.5mM ethylenediamine-
tetraacetic acid (EDTA), 150mg/ml bovine serum albumin
(BSA), 40mM ADP, 0.015% Nonidet P-40, 15% glycerol),
and then incubated with radiolabeled DNA substrate
(10nM) in a 10ml reaction volume at 308C for 20min.
DNA–protein samples were electrophoresed through a
6% (37.5:1 acrylamide:bis-acrylamide) native PAGE
with 2.5% glycerol in 1  TGE buﬀer (25mM Tris–HCl,
pH 8.2, 192mM glycine, 1mM EDTA) at 100V for 1.5h
at 48C. The gel was dried at 858C for 2.5h, and DNA–
protein complexes on the gel were visualized using a
PhosphorImager Typhoon 9410 (GE Healthcare Life
Sciences, Piscataway, NJ, USA). The scanned image
was quantiﬁed using the ImageQuant software (GE
Healthcare Life Sciences) and processed Photoshop CS3
software program (Adobe Systems Incorporated, San
Jose, CA, USA).
Southwestern analysis
The DNA–protein complexes were separated from the free
DNA and protein using native PAGE as described above.
The gel was exposed to X-ray ﬁlm (Eastman Kodak,
Rochester, NY, USA) without drying, and then trans-
ferred onto a 0.45mm polyvinylidene ﬂuoride (PVDF)
membrane (Milipore, Billerica, MA, USA) using a semi-
dry transfer unit (Hoefer, San Francisco, CA, USA) in a
transfer buﬀer [39mM glycine, 48mM Tris, 0.1% sodium
dodecyl sulfate (SDS), 20% methanol] at 1mA/cm
2 for
1h. The membrane was washed with Tris–buﬀered saline
containing 0.1% Tween-20 (TBST) and blocked with
TBST containing 2% nonfat dry milk powder (Bio-Rad,
Hercules, CA, USA). The membrane was then probed
with an a-MSH2 antibody (Calbiochem, San Diego, CA,
USA) at a dilution of 1:1000 at room temperature for 2h,
washed with TBST, and incubated with a horseradish per-
oxidase (HRP)-conjugated antibody against mouse IgG
(Bio-Rad) at room temperature for 1h. The membrane
was then washed three times with TBST before being
developed using an ECL Plus chemiluminescence detec-
tion kit (GE Healthcare Life Sciences). Following detec-
tion of MSH2, the membrane was stripped using Strip
buﬀer (Pierce, Rockford, IC, USA) and re-probed with
an a-RPA/p34 antibody (NeoMarkers, Fremont, CA,
USA) at a dilution of 1:500 to detect RPA, or with a
maltose-binding protein (MBP)-tagged antibody (a-MBP
antibody, New England Biolabs, Beverly, MA, USA)
at a dilution of 1:10000 to detect the XPA-MBP or the
XPC–MBP fusion protein.
ChIP assays
ChIP assays were performed using a Simple Chip
Enzymatic Chromatin IP Kit (Cell Signaling, Inc., Santa
Cruz, CA, USA) according to the manufacturer’s
recommended protocol with some modiﬁcation. In brief,
293T human cells ( 1x10
6 per sample) were transfected
with pSupFG1 plasmid only or pSupFG1 plasmid con-
taining a Tdp-ICL. At 24h after transfection, cells were
ﬁxed with 1% formaldehyde for 8min at room tempera-
ture to crosslink DNA and proteins. Crosslinking was
quenched with 125mM glycine, cells were lysed, and chro-
matin was fragmented by partial digestion with micrococ-
cal nuclease and later sonicated to obtain an average
DNA fragment length of 200–500bp. Following sonica-
tion, centrifugation was performed at 12000r.p.m. for
10min at 48C to remove the soluble supernatant. Next,
chromatin was diluted 10-fold with ChIP dilution buﬀer
(0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA,
16.7mM Tris–HCl, pH 8.1, 167mM NaCl) and pre-
cleared with protein-G magnetic beads containing
salmon sperm DNA and BSA. Approximately 1% of the
total chromatin was stored as input DNA and the remain-
ing pre-cleared chromatin (1ml) was incubated with 5mg
of speciﬁc antibody (a-MSH2 antibody, Cell signaling,
or a-MSH3 antibody, Abcam, Cambridge, MA, USA)
or control a-IgG antibody (mouse IgG; Upstate,
Thermeula, CA, USA) and samples were incubated over-
night at 48C on a rotator. Then the immunoprecipitation
complexes were isolated by adding protein G magnetic
beads, rotating for 2h at 48C and beads were collected
by applying a magnetic force. Immunoprecipitated com-
plexes were washed sequentially for 5min three times with
low salt buﬀer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris–HCl, pH 8.1, 150mM NaCl), one
time with high salt buﬀer (0.1% SDS, 1% Triton X-100,
2mM EDTA, 20mM Tris–HCl, pH 8.1, 500mM NaCl),
and then twice with TE buﬀer (10mM Tris–HCl, 1mM
EDTA, pH 8.0). The immunocomplexes were then eluted
by resuspending the beads in 150ml of elution buﬀer (1%
SDS, 0.1M NaHCO3) for 20min at room temperature.
The DNA–protein crosslinks were reversed by heating at
668C in a water bath for 6h with the addition of 5M NaCl
to a ﬁnal concentration of 200mM. All the samples were
then treated with RNase A at 378C for 30min, and then
with Proteinase K at 458C for 1.5h to remove RNA and
protein. Next, the DNA fragments were puriﬁed using
QIAquick PCR puriﬁcation kit (QIAGEN, Valencia,
CA, USA). Fractions of puriﬁed ChIP DNA and input
DNA were used for PCR analysis. The PCR reaction
was performed with AmpliTaq Gold DNA polymerase
(Applied Biosystems Inc, Foster City, CA, USA) for 28
cycles of 30s at 958C, 30s at 568C, and 45s at 728Ci na
Bio-Rad I-cycler. The primers for PCR ampliﬁcation were:
Primer P1, 50-gcc ccc ctg acg agc atc ac; Primer P2, 50-tag
tta ccg gat aag gcg cag cgg; Primer P3, 50-aat acc gcg cca cat
agc ag; and Primer P4, 50-agt att caa cat ttc cgt gtc gcc
(Figure 2A). Ampliﬁed products were separated on 1.5%
agarose gels containing ethidium bromide and visualized
on an AlphaImager (San Leandro, CA, USA).
Antibody supershift assays
DNA–protein complexes were formed under the same
reaction conditions as described above. After incubation
at 308C for 5min, 0.2mg of an antibody against RPA
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MSH3 (a-MSH3 antibody) was added to the reaction, and
incubation was continued at 308C for 20min. Samples
were electrophoresed through a 4% native PAGE (37.5:1
acrylamide/bis-acrylamide) in 1  TGE buﬀer at 48C
(25mA) for 2–3h. The gels were then dried and visualized
using autoradiography.
RESULTS
Recognition of Tdp-ICLs by MutSb
Tdp-ICLs and ICLs alone (in the absence of the TFO)
represent complex DNA lesions that may be recognized
by proteins from more than one DNA repair mechanism.
Similar to NER mutant cell lines, cells deﬁcient in
the MMR protein MSH2 exhibited impaired repair of
Tdp-ICLs or ICLs only in vivo (20). Gel-shift assays
have demonstrated that MutSb recognizes duplex ICLs
induced by psoralen (15). To determine if MutSb could
recognize psoralen ICLs in the presence of a triplex struc-
ture (i.e. Tdp-ICLs), we performed EMSAs with puriﬁed
human recombinant MutSb protein complex and radiola-
beled Tdp-ICL substrate. The Tdp-ICL substrate contains
a 57-bp DNA duplex of two 50-end-
32P-labeled comple-
mentary oligonucleotides (71+72; Figure 1A). The
duplex was crosslinked to a 50-psoralen-coupled 30-nt
TFO (pAG30; Figure 1A), which has been used
previously to study the function of NER proteins in the
recognition of Tdp-ICLs (17,18,21). By EMSA analysis,
we found that puriﬁed MutSb [at 43nM, the estimated
apparent Kd (Kapp); data not shown] bound to the Tdp-
ICL substrate (at 10nM), forming a complex that
migrated more slowly than the unbound Tdp-ICL
Figure 1. Speciﬁc recognition of Tdp-ICLs by MutSb.( A) Sequences of the 57-bp DNA duplex (complementary oligonucleotides 71+72) and the
50-psoralen-conjugated TFO (pAG30) used to form the Tdp-ICL substrate. The 50-TpA psoralen crosslinking site is shown in the box. (B) EMSA
analysis of MutSb (43nM) on Tdp-ICLs (10nM) with unlabeled Tdp-ICLs or unlabeled DNA duplex used as competitor. The concentrations of the
competitors were at 2 ,1 0   and 50  of the 50 end g-
32P labeled Tdp-ICL substrate. Puriﬁed MutSb was incubated with labeled Tdp-ICLs at 308C
for 5min prior to the addition of the competitor DNA. Incubation was then continued for 20min. The resulting DNA–protein complexes were
separated from the free DNA substrate and unbound protein using 6% native PAGE. The gel was then dried and scanned using a PhosphorImager.
Lane 1, DNA substrate only; lane 2, MutSb; lanes 3–5, MutSb with additional unlabeled competitor Tdp-ICL substrate; lanes 6–8, MutSb with
additional unlabeled competitor duplex DNA. (C) Quantitation of Mutsb bound to the Tdp-ICL (radioactivity in the band containing MutSb as a
percentage of the total radioactivity loaded in the lanes from Figure 1B). (D) Southwestern blotting analysis of the MutSb–DNA complex and
unbound MutSb. The MutSb–DNA complex or MutSb alone was separated using 4% native PAGE, and then transferred onto a PVDF membrane
after exposure to X-ray ﬁlm. The membrane was probed with an a-MSH2 antibody to detect MutSb.
Nucleic Acids Research, 2009,Vol.37, No. 13 4423(Figure 1B, indicated by arrows). We observed a similar
mobility shift when we incubated MutSb with a PAGE
puriﬁed Tdp-ICL substrate (Figure S1), while MutSb (at
the same concentration) showed no detectable binding
to the non-damaged DNA duplex control substrate.
To determine the speciﬁcity of MutSb binding to the
Tdp-ICL, increasing amounts of unlabeled Tdp-ICL
were added to the reaction as a competitor. Unlabeled
Tdp-ICL eﬀectively competed with labeled Tdp-ICL sub-
strate, leaving few detectable shifted complexes (of MutSb
bound to the radiolabeled Tdp-ICL) on the gel (Figure 1B
and C, compare lanes 2 and 5). In contrast, addition of
the same amount of unlabeled duplex DNA competitor
in the reaction served as a much less eﬃcient competitor
(Figure 1C). Higher concentrations of the unlabeled
duplex substrate (50 ) were able to compete for MutSb
binding to some extent, demonstrating that MutSb can
bind with low aﬃnity to duplex DNA non-speciﬁcally
under the conditions of our assay (Figure 1B and C,
compare lanes 5 with 8). The presence of MutSb in the
slower migrating complex was conﬁrmed by Southwestern
blotting analysis (Figure 1D), which showed that Tdp-
ICL-bound MutSb migrated slightly faster than the
unbound MutSb protein in the absence of DNA substrate.
Taken together, these results suggest that MutSb binds
to Tdp-ICLs with high aﬃnity and speciﬁcity.
To investigate the extent to which MutSb recognized
the ICL versus the triple-helical structure formed by the
TFO (in addition to the ICL induced by psoralen), we
analyzed the binding of MutSb to a Tdp-ICL (triplex
ICL) compared to a duplex ICL after removal of the
TFO from the Tdp-ICL substrate. MutSb bound to the
psoralen ICL in the absence of triplex formation, consis-
tent with previous ﬁndings (15). The binding aﬃnity of
MutSb for the duplex ICL was slightly less than that
of the Tdp-ICL (Figure S2), indicating that the triple heli-
cal structure enhances the recognition of Tdp-ICLs by
MutSb. We were unable to examine binding of MutSb
to a DNA triplex in the absence of the ICL (triplex
only), because the triplex structure was not stable under
the conditions of our assays.
MutSb interacts with Tdp-ICLs in human cells
We have shown that MutSb binds Tdp-ICLs using
an in vitro puriﬁed system. To conﬁrm that this is a phys-
iologically relevant interaction, we performed ChIP
experiments to assess the binding of MutSb in human
cells. The pSupFG1 plasmid (Figure 2A) containing a
Tdp-ICL (at the same location as that of the 71+72 syn-
thetic duplex substrate; see Figure 1A), or pSupFG1 plas-
mid alone (18) were transfected into 293T human cells.
Twenty-four hours after transfection, cells were harvested
and chromatin was immunoprecipited (as described in
the ‘Materials and Methods’ section) using an a-MSH2,
a-MSH3, or a control a-IgG antibody. Input and immu-
noprecipited DNA samples were ampliﬁed by semi-
quantative PCR (Figure 2B and C) with speciﬁc primers
(P1 and P2) near the ICL and another set of primers (P3
and P4)  2kb from the ICL to serve as an internal control
for the eﬃciency of immunoprecipitation. As shown
in Figure 2B and C, we observed that the a-MSH2 and
a-MSH3 antibodies were able to pull down more
pSupFG1 DNA containing the Tdp-ICL as compared
to the pSupFG1 control plasmid in the absence of the
Tdp-ICL (Figure 2B and C, compare lanes 6 and 7). As
expected, the amount of total DNA from cell lysates was
similar in each sample as assessed by the amount of
DNA ampliﬁed using either primer set (Figure 2B and
C, ‘Input’ lanes). An IgG antibody was used as an anti-
body speciﬁcity control, and as expected, we did not
observe a signal in the IgG antibody samples (Figure 2B
Figure 2. MSH2 binds to a Tdp-ICL in human cells. (A) Schematic
representation of plasmid, pSupFG1, containing the same TFO binding
site as in the synthetic duplex 71+72, adjacent to a psoralen cross-
linking site, and primer sites (P1, P2, P3 and P4) on the plasmid used
for ChIP analysis. (B and C) Representative agarose gels of PCR pro-
ducts from ChIP assays demonstrating the binding of the a-MSH2 or
a-MSH3 antibody to DNA near the site of the Tdp-ICL. Puriﬁed DNA
was analyzed by standard PCR methods using primers P1 and P2 (near
the TFO binding and psoralen crosslinking site) and control primers P3
and P4 ( 2kb from the TFO binding and psoralen crosslinking site).
Lane 1, PCR control without input template; lanes 2–7, PCR products
ampliﬁed with primers P1 & P2; lanes 8–13, PCR products ampliﬁed
with primers P3 & P4; C, PCR control without template; ‘–’ template
from untransfected cells; ‘+’ template from the cells transfected with
plasmid; G, pulldowns with a-IgG antibody; P, template from the cells
transfected with the control plasmid; X, template from the cells trans-
fected with the plasmid containing the Tdp-ICL. M, 100bp DNA
ladder (Bio-Rad).
4424 Nucleic Acids Research, 2009, Vol. 37,No. 13and C, lanes 5 and 11). This result indicates that
the human mismatch repair protein complex, MutSb
recognizes and binds Tdp-ICL-damaged DNA to
a greater extent than it does to non-damaged DNA
in human cells, consistent with our EMSA data (see
Figure 1).
Formation of MutSb and XPA–RPA complexes on
Tdp-ICLs
Previously, we observed that proteins in the NER
pathway (XPA, RPA, and XPC–RAD23B) function in
the recognition of Tdp-ICLs (17,18,21). To determine
whether MutSb interacts with these NER proteins in the
recognition of Tdp-ICLs, we conducted EMSA analysis
with puriﬁed recombinant human MutSb and XPA–
RPA at their estimated Kapp concentrations [XPA
60nM; RPA 4nM; (18)]. Both the XPA–RPA complex
and the MutSb heterodimer recognized the Tdp-ICL indi-
vidually, as evidenced by shifted substrates detected by
EMSA (Figure 3A, indicated by arrows). However,
when both XPA–RPA and MutSb were incubated
simultaneously with the Tdp-ICL substrate, a slowly
migrating band was detected on the gel, suggesting that
both protein complexes bound the Tdp-ICL and together
formed a multimeric complex with the Tdp-ICL
(Figure 3A, lane 4).
In this slower migrating complex, binding of XPA–RPA
and MutSb to the DNA substrate appeared to be speciﬁc
to the Tdp-ICL, as the radiolabeled complex was dimin-
ished in the presence of unlabeled Tdp-ICL but not by
unlabeled duplex DNA (Figure 3A and B, compare lane
7 with lane 10). We observed similar binding of XPA–
RPA and MutSb to puriﬁed Tdp-ICLs (Figure S1), but
not to the non-damaged duplex DNA, which further sug-
gested that these proteins bind speciﬁcally to the Tdp-ICL.
The binding aﬃnity of XPA–RPA to duplex ICLs (in the
absence of the triplex structure) was approximately an
order of magnitude lower than for Tdp-ICLs. XPA–
RPA and MutSb bound together to a duplex ICL sub-
strate (in the absence of the TFO), but again the binding
aﬃnity was approximately an order of magnitude lower
than for Tdp-ICLs (data not shown), suggesting that
TFO-directed triplex formation enhanced the recognition
of the ICL by repair proteins.
The presence of both XPA–RPA and MutSb in the
higher-order complex was demonstrated by antibody
supershift analysis (Figure 3C) and further conﬁrmed by
Western blotting analysis (Figure S3). We observed a
supershift of the slower migrating band on the gel when
an a-RPA/p34 antibody was added to the reaction
(Figure 3C, indicated by double triangles), and a super-
shifted band on the gel (Figure 3C, indicated by double
stars) with the addition of an a-MSH3 antibody. We fur-
ther conﬁrmed the presence of this a-MSH3-shifted com-
plex on a 4% native PAGE (Figure S4). Together, the
presence of XPA, RPA, and MutSb with the Tdp-ICLs
in this complex was conﬁrmed using Western blotting
(Figure S3) and antibody supershift analysis (Figures 3C
and S4), indicating that MutSb and XPA–RPA bound
together on Tdp-ICLs.
Figure 3. Formation of complexes of MutSb and XPA–RPA on Tdp-
ICLs. (A) The puriﬁed human recombinant protein complexes MutSb
(43nM) and XPA–RPA (XPA at 60nM; RPA at 4nM, pre-incubated)
were added alone or together to Tdp-ICLs (10nM). The protein–DNA
complexes are indicated by arrows. An unlabeled Tdp-ICL or DNA
duplex competitor was added to the reaction at 2 ,1 0   and 50  the
[g-
32P]dATP-labeled Tdp-ICL substrate concentration (10nM). Lane 1,
DNA substrate only; lanes 2–4, DNA substrate with indicated proteins;
lanes 5–7, MutSb and XPA–RPA with increased unlabeled Tdp-ICL
competitor; lanes 8–10, MutSb and XPA–RPA with increased
unlabeled DNA duplex competitor. Binding of multiple MutSb mole-
cules to Tdp-ICLs is indicated with a black dot. (B) Quantitation of
MutSb and XPA–RPA bound to the Tdp-ICL (radioactivity in the
band containing both MutSb and XPA–RPA as a percentage of the
total radioactivity loaded in the lanes from Figure 3A). (C) Antibody
supershift assay of MutSb and XPA–RPA on the Tdp-ICL. The pur-
iﬁed protein complexes were incubated with the Tdp-ICLs at 308C for
5min and then incubated with an antibody (a-RPA/p34 or a-MSH3,
0.2mg each) for 20min. The DNA–protein complexes were separated
from the free DNA substrate using 6% native PAGE. The protein–
DNA complexes are indicated by arrows. The triangle marks the XPA–
RPA–Tdp-ICL complex shifted by an a-RPA/p34 antibody; the double
triangle marks the MutSb–XPA–RPA–Tdp-ICL complex shifted by an
a-RPA/p34 antibody; the star marks the MutSb–Tdp-ICL complex
shifted by an a-MSH3 antibody; the double star marks the MutSb–
XPA–RPA–Tdp-ICL complex shifted by an a-MSH3 antibody.
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When we incubated both MutSb and XPA–RPA with a
Tdp-ICL, a higher-order complex formed in addition
to two faster migrating complexes representing discrete
binding of either MutSb or XPA–RPA to the Tdp-ICL
(see Figure 3). Decreasing the amount of the DNA sub-
strate in the reactions resulted in an increase in the ratio of
the slower migrating complex (containing both MutSb
and XPA–RPA bound to the Tdp-ICL) to the faster
migrating complexes (containing Tdp-ICL with either
MutSb or XPA–RPA; Figure 4A and B). This interaction
appeared to be speciﬁc to the Tdp-ICL, because the total
amount of non-damaged duplex DNA substrate remained
similar in all samples (Figure 4B).
In order to determine if the binding of one of the pro-
tein complexes to the Tdp-ICL substrate inﬂuenced the
binding of the other protein complex, we performed
order-of-addition experiments. We observed that either
protein complex alone could recognize Tdp-ICLs within
1min after incubation (data not shown). As shown
in Figure 4C, the higher-order complex containing
XPA–RPA, MutSb, and the Tdp-ICL was formed on a
pre-formed complex of XPA–RPA–Tdp-ICL or on a pre-
formed complex of MutSb–Tdp-ICL. Thus, interaction
between MutSb and XPA–RPA occurs on Tdp-ICLs
regardless of their order of addition to the reaction.
Independent binding of Tdp-ICLs to MutSb and
XPC–RAD23B at Kapp protein concentrations
XPC–RAD23B is thought to be the ﬁrst damage recogni-
tion factor in the NER pathway to bind DNA damage
(13,28). Because we observed that XPA–RPA interacted
with MutSb on Tdp-ICLs, we were compelled to deter-
mine whether MutSb interacted with XPC–RAD23B on
TFO-directed psoralen ICLs. To further delineate the pro-
teins involved in the recognition of Tdp-ICLs, we con-
ducted EMSA analysis with MutSb and XPC–RAD23B
as described above for MutSb and XPA–RPA. At its Kapp
concentration, XPC–RAD23B (6.5nM) formed a complex
with the Tdp-ICL (Figure 5A, lane 2), consistent with our
previously published results (17). In contrast to the inter-
action identiﬁed between MutSb and XPA–RPA, incuba-
tion of MutSb and XPC–RAD23B with Tdp-ICLs
resulted in the formation of two discrete complexes with
Tdp-ICLs (Figure 5A, lane 5). Southwestern blot analysis
conﬁrmed that the two individual complexes were com-
posed of either MutSb with Tdp-ICLs or XPC–RAD23B
with Tdp-ICLs (Figure 5B). In the presence of an a-MBP
antibody, which was able to recognize the MBP-fused
XPC protein, only the band containing XPC–RAD23B
was supershifted, while the complex containing MutSb
bound to Tdp-ICLs maintained its mobility on the gel
(Figure 5A), suggesting that XPC–RAD23B and MutSb
bound to Tdp-ICLs in an independent fashion. We also
observed independent binding of these two complexes
with puriﬁed Tdp-ICLs (Figure S5) or duplex ICLs
(data not shown) at Kapp concentrations. Similar to that
of XPA–RPA, the binding of XPC–RAD23B to duplex
ICLs (in the absence of the triplex structure) was
decreased, consistent with our previous report (17).
Figure 4. MutSb and XPA–RPA interact on Tdp-ICLs. (A) EMSA
analysis of puriﬁed MutSb and XPA–RPA complexes with decreasing
concentrations of the Tdp-ICL substrates. Lane 1, DNA substrate; lane
2, MutSb; lane 3, XPA–RPA and MutSb; lanes 4–6, MutSb and XPA–
RPA with decreasing amounts of DNA substrate (1/2 , 1/4  and 1/
8 , respectively, of 10nM). The protein–DNA complexes are indicated
by arrows. (B) Quantitation of MutSb–XPA–RPA–Tdp-ICL complex
bands and duplex DNA bands as the percentage of total DNA sub-
strate (Sub) loaded in lanes 3–6 in Figure 4A. (C) EMSA analysis of
the Tdp-ICLs with sequential addition of puriﬁed MutSb or XPA–
RPA. Lane 1, DNA substrate; lane 2, MutSb; lane 3; XPA and
RPA; lane 4, MutSb and XPA–RPA; lanes 5–7, samples were incu-
bated with MutSb at 308C for 10min, then XPA–RPA (at 1 ,2  
and 5  of 60nM/4nM) was added, and the samples were incubated
for another 10min. Lanes 8–10, samples were incubated with XPA–
RPA at 308C for 10min, then MutSb (at 1 ,2   and 5  of 43nM)
was added, and samples were incubated for another 10min. The DNA–
protein complexes were separated from free DNA substrate using 6%
native PAGE. The black dot marks the multiple binding of MutSb to
the Tdp-ICL.
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XPC–RAD23B or MutSb to psoralen ICLs may exclude
the binding of the other protein complex to the same
molecule. This diﬀerential binding of the lesion by the
NER and MMR protein complexes may result in diﬀer-
ential processing of the lesion. However, either of these
complexes can interact with XPA–RPA on Tdp-ICL
(as shown above and ref. 17), such that the binding of
MutSb to psoralen ICLs might also facilitate repair of
the lesion by NER proteins. Similar to our results with
XPA–RPA, XPC–RAD23B and MutSb also formed a
complex together with Tdp-ICLs at increased protein
concentrations (data not shown).
DISCUSSION
Psoralen-modiﬁed TFOs have been used to introduce site-
speciﬁc ICLs in genomic DNA in cells, which may provide
a means to improve upon ICL-based chemotherapeutic
strategies. In this study, we found that the MMR complex
MutSb bound to TFO-directed psoralen ICLs with high
speciﬁcity and aﬃnity, and interacted with the NER
complex XPA–RPA, in recognizing these lesions in our
puriﬁed in vitro system.
The recognition and processing of Tdp-ICLs may diﬀer
from that of duplex ICLs, as TFO binding to the DNA
duplex may prevent binding and/or cleavage of damaged
DNA strands by repair proteins (29). However, the pres-
ence of the third strand TFO adjacent to the duplex ICLs
may increase the structural distortion at the site of
damage, and as a consequence, recruit repair proteins
more eﬃciently. In support of this idea, Christensen
et al. (19) demonstrated that the bacterial UvrABC nucle-
ase incised TFO-directed psoralen ICLs with a similar
pattern, but greater eﬃciency than psoralen ICLs alone.
Consistent with this, the work described here demon-
strated that the NER and MMR damage recognition pro-
teins bound the TFO-directed psoralen ICLs with greater
aﬃnity than they did the psoralen ICLs in the absence of
the TFO, and thus the TFO may promote more eﬃcient
repair of ICLs. Despite their structural diﬀerences, both
the TFO-directed ICLs and the ICLs alone were recog-
nized by the same protein complexes, suggesting that the
triplex structure itself may be repaired in a fashion similar
to that of the ICL alone. Therefore, psoralen-modiﬁed
TFOs can be used to facilitate mechanistic studies of
ICL processing and repair by creating ICLs at speciﬁc
sites in the genome. In addition, direct substrate compar-
isons can be made between Tdp-ICLs and ICLs (in the
absence of the TFO) by facile removal of a disulﬁde linked
TFO-psoralen conjugate following crosslink formation,
as we have demonstrated in this study and in a previous
report (19).
Although the binding of both NER and MMR com-
plexes to Tdp-ICLs was detected in our in vitro system,
we cannot rule out the possibility that the binding of these
two complexes on the same molecule may lead to the
diﬀerential processing of the lesions. For example, some
lesions may be repaired in an error-free pathway with
MutSb, while others are repaired via an error-prone
pathway with NER, as suggested previously (16,18,20).
However, it maybe too simple to classify these protein–
protein, and DNA–protein interactions into two indepen-
dent pathways. In fact, the data presented here suggest
that the binding of MutSb to Tdp-ICLs may facilitate
the recruitment of the XPA–RPA complex (required for
Figure 5. Independent binding of MutSb and XPC–RAD23B to Tdp-
ICLs at low (Kapp) protein concentrations. (A) EMSA analysis of pur-
iﬁed human recombinant MutSb (43nM) and XPC–RAD23B (6.5nM)
with Tdp-ICLs (10nM). An a-MBP antibody was used to supershift the
XPC–RAD23B–Tdp-ICL complex (by identiﬁcation of the MBP-tagged
XPC protein). Lane 1, DNA substrate; lane 2, XPC–RAD23B; lane 3,
XPC–RAD23B and a-MBP antibody; lane 4, MutSb; lane 5, XPC–
RAD23B and MutSb; lane 6, XPC–RAD23B, a-MBP antibody and
MutSb. The star marks the protein–DNA complex shifted by an
a-MBP antibody. (B) Southwestern blot analysis of the DNA-protein
complexes and unbound proteins using 4% native PAGE. The gels
were exposed to X-ray ﬁlm and then transferred to a PVDF membrane.
The membrane was probed with the a-MSH2 antibody and then
stripped and blotted again with the a-MBP antibody.
Nucleic Acids Research, 2009,Vol.37, No. 13 4427both global and transcription-coupled NER), but not the
XPC–RAD23B complex (required only for global NER)
to sites of DNA damage. These results provide a plausible
explanation for the requirement for XPA, but not XPC in
TFO-induced mutagenesis in mammalian cells (30,31).
In normal cells, the concentration of MutSb is lower
than NER proteins [MutSb:  1 10
3 (24); XPC:
 5 10
4; RPA:  3 10
5; XPA:  5 10
4 molecules per
cell (32–34)]. However, we cannot rule out that during
active replication, the participation of MutSb in ICL pro-
cessing is likely to take place where the local concentration
of MutSb may be higher, such that an interaction with
NER factors on ICLs is favored. In fact, at higher protein
concentrations (i.e. 5-fold above the Kapp concentration of
either XPC–RAD23B or MutSb), we observed the forma-
tion of a higher-order complex containing both XPC–
RAD23B and MutSb bound to Tdp-ICLs (data not
shown), suggesting that MutSb and XPC–RAD23B may
act together to recognize the Tdp-ICL when the relative
concentrations of the proteins are higher than that of the
damaged DNA substrate.
The canonical function of MMR is to recognize mis-
matched basepairs during replication to ensure genomic
integrity (35). In addition to this function MutSb has
been found to promote trinucleotide repeat (TNR) expan-
sion and to prevent the repair of TNR hairpins, perhaps
due to its decreased ATPase activity after binding to
imperfect hairpins (36). In addition, MSH2 can bind to
repetitive slipped-strand DNA structures and prevent
homologous recombination at those sites (37). The psor-
alen ICL-induced sensitivity of cells deﬁcient in MutSb,
but not in MLH1 demonstrates that MutSb functions in
ICL processing independent of its role in MMR (20,38).
The role of MutSb in processing ICLs in cells is still not
clear. Based on our previous work, it is not unreasonable
to assume that the binding of MutSb to the ICL eventually
results in its eﬃcient processing and removal from
the DNA (20). In addition to NER and MMR factors,
proteins functioning in base excision repair may excise
monoadducts induced by psoralen (39,40). ICLs may
also be repaired by proteins from diﬀerent repair path-
ways in a cell-cycle-dependent fashion (41). ICL proces-
sing and repair in human cells is more complicated than in
bacterial cells, and likely involves a combination of or
competition between proteins functioning in diﬀerent clas-
siﬁed repair pathways. Further investigations on the inter-
action between MutSb, NER proteins, and downstream
repair factors on ICLs are warranted.
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